Aptose Biosciences (APTO) said Monday that it has regained compliance with Nasdaq's minimum bid price requirement.
The company said it received a written notice for the compliance from the stock exchange on Friday after having a closing bid price of $1 or greater for 10 consecutive business days.
Aptose also said it is not in compliance with the $2.5 million stockholders' equity requirement of Nasdaq and is operating under an exception granted by the hearing panel of the stock exchange, which allows for additional time to regain compliance.